VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
2 hedge funds and large institutions have $3.11K invested in VALEANT PHARMACEUTICALS INTL in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
88% less capital invested
Capital invested by funds: $25K → $3.11K (-$21.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
+$1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AlphaMark Advisors
Ft. Wright,
Kentucky
|
-$19K |
VRX Hedge Fund Activity: Q1 2016 in Review
2 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q1 2016, worth a combined $3.11K — down 88% from $25K a quarter earlier.
Fund positioning in VRX was balanced in Q1 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was TCI Wealth Advisors, opening a new position worth an estimated $1K. The largest seller was AlphaMark Advisors, exiting entirely with an estimated $19K sold.
- 2 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $3.11K of VALEANT PHARMACEUTICALS INTL stock for Q1 2016, down 88% quarter-over-quarter.
- 1 fund opened new VALEANT PHARMACEUTICALS INTL positions in Q1 2016 and 1 closed out, a net change of 0 holders.
- The largest VALEANT PHARMACEUTICALS INTL buyer in Q1 2016 was TCI Wealth Advisors, an estimated $1K added.
- The largest VALEANT PHARMACEUTICALS INTL seller in Q1 2016 was AlphaMark Advisors, an estimated $19K sold.
Based on aggregated 13F filings for Q1 2016.